Iron Therapy in Erythropoietic Protoporphyria

Completed

• Conditions: Erythropoietic Protoporphyria; Iron-deficiency

• Registration Number: NCT05572125
• Lead Sponsor: Bispebjerg Hospital

Brief Summary

Giving oral iron to patients with erythropoietic protoporphyria (EPP) who is iron deficient is thought to be beneficial. This is, however, not well documented. The purpose of this study is to investigate the effect and safety of oral iron in patients with EPP who is taking iron tablets due to iron deficiency.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-05
• Study First Submitted QC: 2022-10-05
• Study First Posted: 2022-10-07
• Study Start: 2022-10-17
• Status Verified: 2023-02
• Primary Completion: 2023-02-14
• Study Completion: 2023-02-14
• Last Update Submitted: 2023-02-22
• Last Update Posted: 2023-02-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Diagnosed with EPP
• Taking standard dose of iron tablets due to iron deficiency

Exclusion Criteria

• Pregnant
• Lactating

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in erythrocyte protoporphyrin concentration	Before treatment and after 6-8 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
Change in hemoglobin and iron parameters	Before treatment and after 6-8 weeks of treatment
Adverse event	6-8 weeks of treatment

Trial Locations

Locations (1)

Bispebjerg Hospital; 🇩🇰 Copenhagen, Denmark